An interventional study of Effect of polyphenols on hepatic steatosis and vascular elastography and intima media thickness in Obesity, Childhood, Hepatic Steatosis and Intimal Hyperplasia, sponsored by St. Justine's Hospital. Recruiting at 1 site in Canada. Open to participants aged 12 Years to 18 Years. Per ClinicalTrials.gov, last updated 2024-01-23.
Sponsored by St. Justine's Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 51 studies in Pediatric Obesity with a site in Canada — 7 open to participants now, 9 under way, 1 of them phase 3. Pediatric Obesity · Canada.
Among the 51 studies in Pediatric Obesity with a site in Canada, this one is the 23rd largest by planned enrollment of the 40 interventional ones that give a count, is one of 6 that started in 2021, is one of 37 with no phase, and was the 35th registered.
1,132 studies on the registry are indexed under Pediatric Obesity; 183 are open to participants now.
Browse Pediatric Obesity studies →7 of the 51 studies in Pediatric Obesity with a site in Canada are open now. Recruiting first, the newest first:
Hamilton Health Sciences Corporation · Sites in Canada
Ages 5–11 · Healthy volunteers
University of Victoria · Sites in Canada
Ages 6–12 · Healthy volunteers
University of Alberta · Sites in Canada
Ages 12–18
The Hospital for Sick Children · Sites in Canada
Ages 18 mo–60 mo · Healthy volunteers
University of Alberta · Sites in Canada
Ages 6–17
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 119 Pediatric Obesity studies recruiting now, 16 (13%) set no upper age limit and 101 (85%) stop at 75 or younger; 110 take children under 18; 67 take healthy volunteers.
This study: 12 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
51 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 6 started in 2021.
This study's planned enrollment of 60 is below the median of 100 across 872 interventional studies indexed under Pediatric Obesity.
Median enrollment 73 across the 40 interventional studies, 54 across the 11 observational. Of the 36 that completed or were terminated, 2 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 51 has an industry lead sponsor. The 10 most frequent:
St. Justine's Hospital is the lead sponsor of 156 studies on the registry; 27 are open to participants now.
St. Justine's Hospital has 2 studies filed under Pediatric Obesity — fewer than ten, so there is no comparison to draw.
3 of the studies in Pediatric Obesity with a site in Canada that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04578652Phase 3University of AlbertaFiber and Metformin Combination Therapy in Adolescents With Severe Obesity and Insulin Resistance | 2027-02 |
| NCT05534711University of GuelphThe Family Stress Study - Chronic Stress and Child Adiposity: Testing a Bio-behavioural Model | 2027-05-30 |
| NCT06844786Hamilton Health Sciences CorporationSCORE! ACTIVE Trial | 2027-08-15 |
Add all 3 to your calendar (.ics) → With an account.
Among the 51 studies in Pediatric Obesity with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main objective is to study the effect of polyphenol supplementation on hepatic steatosis as measured by hepatic ultrasound, hepatic magnetic resonance imaging and on intima-media thickness and vascular elastography in obese adolescents known for hepatic steatosis as diagnosed by liver biopsy
Evaluate the feasibility of a larger, open-label, randomized, controlled trial on the effects of polyphenol supplementation:
Recruitment, compliance to polyphenol supplementation and the visit roadmaps Duration of the radiological exams and participants' satisfaction and point of view on the experience. Test the relevance of using a food diary. Test the effectiveness of the data collection procedure during the visits. Explore the obstacles encountered while performing the radiological exams and the rate of adverse events (AE). Calculate the sample size of the future randomized clinical study
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Exclusion criteria to be validated when contacting the participants and their parents/tutors:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
120mg per day of powder polyphenol for 60 days
Dietary Supplement: Effect of polyphenols on hepatic steatosis and vascular elastography and intima media thickness
1 tab PO QD per day of placebo for 60 days
Dietary Supplement: Effect of polyphenols on hepatic steatosis and vascular elastography and intima media thickness
Measurement of effect of polyphenol supplementation vs placebo on hepatic steatosis and vascular elastography and intima media thickness
Recruitment
Rate of recruitment
Time frame: Through study completion an average of 1 year
Retention:
The percentage of adolescents who agree to participate in the study and the retention
Time frame: Through study completion an average of 1 year
Compliance with polyphenol supplementation
Percentage of compliance
Time frame: Through study completion an average of 1 year
Effectiveness of the data collection procedure during the visits
Percentage of completed visits
Time frame: Through study completion an average of 1 year
Adverse event
Percentage of adverse events
Time frame: Through study completion an average of 1 year
Satisfaction of the participants and their point of view on the experience
Percentage of satisfaction of participants enrolled
Time frame: Through study completion an average of 1 year
Sample size calculation for a randomized controlled study
A sample size for a future randomized controlled study will be calculated from the estimates obtained during this pilot study.
Time frame: Through study completion an average of 1 year
Change in hepatic steatosis MR
mDixonQuant in percentage
Time frame: At recruitment, after 60 days, and after 120 days
Change in hepatic steatosis B-mode US
US liver echogenicity normal or increased
Time frame: At recruitment, after 60 days, and after 120 days
Change in intima media thickness (vascular compliance)
Measurement of carotid artery intima media thickness in mm
Time frame: At recruitment, after 60 days, and after 120 days
Metabolic syndrome
Insulin resistance evaluated by HOMA-IR mg\\dl
Time frame: At recruitment, after 60 days, and after 120 days
Cholesterol
Triglyceride index (no unit)
Time frame: At recruitment, after 60 days, and after 120 days
Anthropometric measure
Body mass index
Time frame: At recruitment, after 60 days, and after 120 days
Inflammatory marker 1
CRP
Time frame: At recruitment, after 60 days, and after 120 days
Inflammatory marker 2
TNF alpha
Time frame: At recruitment, after 60 days, and after 120 days
Inflammatory marker 3
IL-6
Time frame: At recruitment, after 60 days, and after 120 days
Lipid markers 1
Triglycerides
Time frame: At recruitment, after 60 days, and after 120 days
Lipid markers 2
LDL
Time frame: At recruitment, after 60 days, and after 120 days
Lipid markers 3
HDL
Time frame: At recruitment, after 60 days, and after 120 days
Lipid markers 4
Apo AI
Time frame: At recruitment, after 60 days, and after 120 days
Lipid markers 5
Apo B-100
Time frame: At recruitment, after 60 days, and after 120 days
Lipid markers 6
Adiponectin, leptin
Time frame: At recruitment, after 60 days, and after 120 days
Liver function test
ALT
Time frame: At recruitment, after 60 days, and after 120 days
Stool test
Gut microbiome composition
Time frame: At recruitment, after 60 days, and after 120 days
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2021 (actual). Primary completion is estimated for Dec 2024, 41 months after the start.
Of 542 non-industry interventional studies with no phase under Pediatric Obesity, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 45. This study's planned 41 months is above that.
Counting every sponsor, half of 544 studies reached it within 25 months; a quarter within 11 and three quarters within 45.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.